NEW YORK (GenomeWeb News) - Johnson & Johnson Pharmaceutical Research & Development will use BioWisdom’s toxicity safety software in drug development programs, BioWisdom said today.
Under the three-year agreement, J&J has joined BioWisdom’s Safety Intelligence Program, which uses the company’s Sofia platform to create a “specialist medical search system” for drug safety risk assessment, BioWisdom said.
The SIP initiative is aimed at helping drug developers avoid drug-induced adverse events, BioWisdom said.
J&J is BioWisdom’s second SIP partner, following AstraZeneca, who joined the program last year.
Financial terms of the agreement were not released.